Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVOK Evoke Pharma	$4.88 -4.9%	$3.36	$1.94 ▼ $12.32	$7.29M	-0.04	1.10 million shs	121,300 shs
KALA KALA BIO	$5.96 +8.8%	$4.36	$2.92 ▼ $11.20	$38.45M	-1.88	49,753 shs	122,126 shs
KPTI Karyopharm Therapeutics	$4.18 -1.4%	$4.68	$3.51 ▼ $16.95	$36.12M	0.24	111,908 shs	96,332 shs
STTK Shattuck Labs	$0.78 -2.0%	$0.98	$0.69 ▼ $4.99	$37.15M	1.63	329,152 shs	186,760 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVOK Evoke Pharma	-10.63%	+92.86%	+77.51%	+136.95%	-27.54%
KALA KALA BIO	-4.04%	+6.01%	+27.21%	+57.64%	-28.12%
KPTI Karyopharm Therapeutics	-11.11%	-8.82%	-3.42%	-4.07%	-70.81%
STTK Shattuck Labs	-3.51%	-2.25%	-21.66%	+4.78%	-82.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EVOK Evoke Pharma	0.8228 of 5 stars	0.0	5.0	0.0	3.1	0.0	0.0
KALA KALA BIO	3.897 of 5 stars	3.5	2.0	4.4	2.3	0.8	0.6
KPTI Karyopharm Therapeutics	3.9673 of 5 stars	3.5	0.0	4.6	2.9	2.5	0.6
STTK Shattuck Labs	3.7027 of 5 stars	3.4	5.0	0.0	3.5	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EVOK Evoke Pharma	0.00	N/A	N/A	N/A
KALA KALA BIO	3.00	Buy	$13.00	118.12% Upside
KPTI Karyopharm Therapeutics	2.80	Moderate Buy	$37.40	794.74% Upside
STTK Shattuck Labs	2.83	Moderate Buy	$7.50	867.12% Upside

Current Analyst Ratings Breakdown

Latest EVOK, KPTI, KALA, and STTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/11/2025	KALA KALA BIO	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
7/11/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00
6/2/2025	KALA KALA BIO	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
5/23/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
5/13/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $42.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EVOK Evoke Pharma	$11.59M	0.63	N/A	N/A	$4.74 per share	1.03
KALA KALA BIO	N/A	N/A	N/A	N/A	$2.02 per share	N/A
KPTI Karyopharm Therapeutics	$145.24M	0.25	N/A	N/A	($22.10) per share	-0.19
STTK Shattuck Labs	$5.72M	6.49	N/A	N/A	$1.67 per share	0.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EVOK Evoke Pharma	-$5.35M	-$2.87	N/A	∞	N/A	-43.80%	-101.91%	-33.75%	8/11/2025 (Estimated)
KALA KALA BIO	-$38.51M	-$8.24	N/A	N/A	N/A	N/A	-369.29%	-64.99%	8/5/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$76.42M	-$13.26	N/A	N/A	N/A	-43.99%	N/A	-35.95%	8/5/2025 (Estimated)
STTK Shattuck Labs	-$75.41M	-$1.39	N/A	N/A	N/A	N/A	-79.69%	-69.13%	7/30/2025 (Estimated)

Latest EVOK, KPTI, KALA, and STTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	EVOK Evoke Pharma	-$0.30	N/A	N/A	N/A	$3.80 million	N/A
8/7/2025	Q2 2025	STTK Shattuck Labs	-$0.25	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	KALA KALA BIO	-$1.82	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	KPTI Karyopharm Therapeutics	-$3.72	N/A	N/A	N/A	$37.92 million	N/A
5/12/2025	Q1 2025	EVOK Evoke Pharma	-$0.33	-$0.51	-$0.18	-$0.51	$3.32 million	$3.08 million
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million
5/1/2025	Q1 2025	STTK Shattuck Labs	-$0.29	-$0.27	+$0.02	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EVOK Evoke Pharma	N/A	N/A	N/A	N/A	N/A
KALA KALA BIO	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EVOK Evoke Pharma	N/A	1.55	1.50
KALA KALA BIO	3.19	1.99	1.99
KPTI Karyopharm Therapeutics	N/A	1.33	1.28
STTK Shattuck Labs	N/A	9.08	9.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EVOK Evoke Pharma	N/A
KALA KALA BIO	24.61%
KPTI Karyopharm Therapeutics	66.44%
STTK Shattuck Labs	58.74%

Insider Ownership

Company	Insider Ownership
EVOK Evoke Pharma	6.10%
KALA KALA BIO	8.32%
KPTI Karyopharm Therapeutics	2.75%
STTK Shattuck Labs	12.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EVOK Evoke Pharma	4	1.49 million	1.40 million	Not Optionable
KALA KALA BIO	30	6.45 million	5.92 million	Not Optionable
KPTI Karyopharm Therapeutics	380	8.64 million	8.40 million	Optionable
STTK Shattuck Labs	100	47.90 million	42.15 million	Optionable

EVOK, KPTI, KALA, and STTK Headlines

Recent News About These Companies

Shattuck Labs Elects Directors, Approves Auditor at Meeting

July 15 at 5:00 PM | tipranks.com

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

July 2, 2025 | globenewswire.com

Shattuck Labs, Inc. (STTK) - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

June 13, 2025 | finance.yahoo.com

Shattuck Labs Advances SL-325 Program Amid Financial Progress

May 5, 2025 | tipranks.com

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025 | globenewswire.com

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

April 2, 2025 | globenewswire.com

Shattuck Labs Full Year 2024 Earnings: Misses Expectations

March 29, 2025 | uk.finance.yahoo.com

Shattuck Labs reports Q4 EPS (37c), consensus (32c)

March 28, 2025 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Hold Rating on Shattuck Labs (STTK)

March 28, 2025 | markets.businessinsider.com

Shattuck Labs, Inc.: Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

March 27, 2025 | finanznachrichten.de

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

March 27, 2025 | globenewswire.com

Leerink Partners Initiates Coverage of Shattuck Labs (STTK) with Outperform Recommendation

March 18, 2025 | msn.com

Shattuck Labs initiated with an Outperform at Leerink

March 17, 2025 | markets.businessinsider.com

Favourable Signals For Shattuck Labs: Numerous Insiders Acquired Stock

March 11, 2025 | finance.yahoo.com

H.C. Wainwright Keeps Their Hold Rating on Shattuck Labs (STTK)

February 21, 2025 | markets.businessinsider.com

Shattuck Labs’ SL-325 shows positive results in inflammatory bowel disease

February 20, 2025 | markets.businessinsider.com

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

February 20, 2025 | globenewswire.com

Shattuck Labs to Present Pre-Clinical Data on SL-325 at ECCO 2025 Conference in Berlin

February 13, 2025 | quiverquant.comQ

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

February 13, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVOK, KPTI, KALA, and STTK Company Descriptions

Evoke Pharma NASDAQ:EVOK

$4.88 -0.25 (-4.87%)

Closing price 04:00 PM Eastern

Extended Trading

$4.96 +0.08 (+1.62%)

As of 04:26 PM Eastern

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

KALA BIO NASDAQ:KALA

$5.96 +0.48 (+8.76%)

Closing price 04:00 PM Eastern

Extended Trading

$5.90 -0.06 (-0.99%)

As of 04:24 PM Eastern

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Karyopharm Therapeutics NASDAQ:KPTI

$4.18 -0.06 (-1.42%)

Closing price 04:00 PM Eastern

Extended Trading

$4.18 +0.00 (+0.12%)

As of 04:13 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Shattuck Labs NASDAQ:STTK

$0.78 -0.02 (-1.98%)

Closing price 04:00 PM Eastern

Extended Trading

$0.78 +0.00 (+0.32%)

As of 04:04 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time